|
04-25-2025 |
National Protocol for Treatment of Chlamydia trachomatis or Neisseria
gonorrhoeae infection in an asymptomatic person |
|
04-15-2025 |
Prevention of hypersensitivity reactions to contrast media |
|
04-08-2025 |
Care Management for Youth under 18 with Attention Deficit Hyperactivity Disorder (ADHD) - Report in Support of the Care Management Tool |
|
03-31-2025 |
Treatment of diarrhea or colitis associated with Clostridioides difficile |
|
02-04-2025 |
Use of antivirals for the treatment and prophylaxis of influenza in children and adults in the context of COVID-19 |
|
01-28-2025 |
Quebec's National Medical Protocol - Pharmacological treatment for fecal elimination in a person receiving palliative care or a person with a geriatric profile
|
|
09-23-2024 |
Hormone therapy for the management of the clinical manifestations of menopause |
|
07-02-2024 |
Judicious blood culture use |
|
09-25-2023 |
Asthma Management in Children and Adults |
|
09-05-2023 |
Submission of surgical specimens to the anatomic pathology laboratory:
relevance and indications |
|
04-11-2023 |
The management of myalgic encephalomyelitis / chronic fatigue syndrome |
|
10-31-2022 |
Usage optimal des immunoglobulines en fertilité, en cardiologie et autres indications |
|
04-19-2022 |
Pénurie d’immunoglobulines – traitements alternatifs aux immunoglobulines humaines non spécifiques |
|
12-12-2021 |
Relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: general surgery, plastic surgery and dermatology |
|
12-12-2021 |
Relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: obstetrics/gynecology and urology |
|
03-30-2021 |
Validation of the management framework for a nonspecific human immunoglobulin shortage |
|
02-05-2021 |
Confirmed Mycoplasma genitalium infection |
|
08-31-2020 |
Quebec's National Medical Protocol - Administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care |
|
06-10-2020 |
Palivizumad (SynagisTM) |
|
05-26-2020 |
Prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes |
|
02-17-2020 |
Recommendations concerning the information required to monitor nusinersen use in real-world settings |
|
01-06-2020 |
Optimal usage guide for immunoglobulins in hematology |
|
08-26-2019 |
Dose banding and dose rounding of antineoplastic agents |
|
07-16-2019 |
Quebec's Medical Protocol - Adjustment of first-line antihypertensive medication |
|
04-03-2018 |
Portrait of opioid use in persons covered by Québec's public prescription drug insurance plan |
|
12-21-2017 |
Usage optimal des antipsychotiques et la prise en charge non pharmacologique des symptômes comportementaux et psychologiques de la démence chez les personnes atteintes de troubles neurocognitifs majeurs qui résident en centre d’hébergement et de soins de longue durée
|
|
09-26-2017 |
Portraits décrivant les interventions pharmacologiques et non pharmacologiques entourant le trouble du déficit de l'attention avec ou sans hyperactivité (TDAH) chez les Québécois de 25 ans et moins |
|
08-09-2016 |
Effet du palivizumab en prophylaxie sur la diminution des complications associées au virus respiratoire syncytial chez les enfants |
|
03-27-2015 |
Guide d'usage optimal pour le traitement pharmacologique de la maladie d'Alzheimer et de la démence mixte |
